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Heart failure (HF) is positively associated with mortality [1,2],
hospital admissions [2], impaired health status [3], and is frequently
accompanied by comorbidities, such as diabetes mellitus (DM) and
chronic obstructive pulmonary disease (COPD) [4,5]. Comorbid DM
and COPD have been found to add to the morbidity in HF in terms of
increased mortality [6] and rates of hospitalization [4], lower quality
of life [5,7], and poorer physical health status [8].
Depressive symptoms and anxiety are common in HF patients
[9,10] and are likely to co-occur [11,12]. However, to date no studies
have examined the effects of comorbid conditions on anxious and
depressive symptoms simultaneously in HF. The course of anxiety and
depression have shown to be stable over time in patients undergoing a
percutaneous coronary intervention (PCI) [13], receiving an ICD [14],
after a myocardial infarction (MI) [15], and atrial ﬁbrillation [16]. Little
is known about the stability of these symptoms in HF patients. One
clinical trial in HF showed that depressive symptoms tended to be
stable over a 6-month period in patients in the control condition [17].
The aims of the current study in HF outpatients were to examine (1)
the stability of depressive symptoms and mixed anxiety and
depressive symptoms after a 12-month period in patients with and
without comorbid DM and or/COPD, and (2) the associations between
comorbid DM and/or COPD and depressive symptoms, and mixed
anxious and depressive symptoms at 12 months.
The sample comprised 350 consecutive HF outpatients (response
rate=70%) recruited between March 2003 and October 2008 from
the three hospitals in the southern regions of the Netherlands.
Inclusion criteria have been described elsewhere [18]. Themean age of
the sample was 66.0±10.4 years, with 250 patients (71.2%) being
men. The study was approved by the medical ethics committees of all
three hospitals, and was conducted according to the Helsinki
Declaration. All patients provided written informed consent and
completed the 21-item Beck Depression Inventory (BDI) [19] and the
4-item Symptoms of Anxiety-Depression Index (SAD4) [20] at
inclusion and 12 months, to assess depressive symptoms and mixed
symptoms of anxiety and depression, respectively.
Twelve-month changes in depressive symptoms and mixed
anxiety and depressive symptoms for the total sample, and for HF
patients with and without comorbid DM or COPD were tested using
paired samples t-tests. Effect sizes (Cohen's d) were calculated to
evaluate clinical relevance of changes [21]. The impact of HF with and
without comorbid DM or COPD on depressive symptoms and mixed
anxiety and depressive symptoms at 12 months were examined by
linear regression analyses. Multivariable analyses were adjusted for
age, gender, current working status, marital status, educational level,
cardiac history, NYHA-class, and LVEF.
In total, 30.9%(n=108) of patients were diagnosed with comorbid
DM and/or COPD. Mean depressive symptoms (8.85±6.12 vs. 8.04±
6.05, t(349)=3.45, p=.001) and mixed anxious and depressive
symptoms (2.28±2.90 vs. 1.93±2.82, t(349)=2.73, p=.007) signiﬁ-
cantly decreased over 12 months for the total sample. The clinical
relevance of these changes were negligible to small (d=0.12). No
differences were observed in baseline depressive symptoms (8.57±6.21
vs. 9.49±5.65, t(348)=−1.29, p=.19) and inmixed symptoms (2.02±
2.79 vs. 2.39±2.94, t(348)=1.12, p=.27) in patients without or with
comorbidities. The prevalence of depressive symptoms (BDI-score≥10)
was 36.3% (127/350) in the total sample, and did not differ in patients
without and with comorbidities (34.3%(83/342) vs. 40.7%(44/108),
χ2=1.34,p=.25). The prevalence of mixed anxiety and depressive
symptoms was 24.3% (85/350), and no differences emerged in patients
with and without comorbidities (23.1%(25/108) vs. 24.8%(60/242),
χ2=0.11,p=.74). Depressive symptoms signiﬁcantly decreased
over 12 months in both the HF group with (9.49±5.66 vs. 8.50±
5.26, t(107)=2.04, p=.04) and without comorbidities (8.57±6.31
vs. 7.84±6.37, t(241)=2.81, p=.005). Mixed anxious and depres-
sive symptoms decreased signiﬁcantly in the group without comor-
bidities (2.39±2.94 vs. 2.04±3.02, t(241)=2.29, p=.02), but not
in those with comorbidities (2.02±2.94 vs. 1.66±2.28, t(107)=
1.49, p=.14). The clinical relevance of all changes was negligible to
small (d=0.18, 0.12, 0.12, and 0.14, respectively). In univariable
analyses, comorbidities were neither associated with depressive
symptoms (B=− .06, 95%CI [− .08 to .02], p=.24) nor with mixed
symptoms (B=.05, 95%CI [− .12 to .33], p=.35). Resultswere similar
in multivariable analyses (Table 1).
Table 1
Multivariable associates of depressive symptoms and mixed anxiety and depressive
symptoms.a
Depressive symptomsb Mixed anxiety and
depression symptomsc
B 95%CI p B 95%CI p
HF with comorbid DM
and/ or COPD
.03 − .07 to .13 .59 − .07 − .16 to .004 .21
Age − .01 − .13 to .11 .89 − .07 − .18 to .06 .29
Female gender .08 − .03 to .18 .17 − .05 − .15 to .06 .41
Having a job − .07 − .19 to .05 .25 − .003 −.12 to .12 .96
Having a partner − .11 − .22 to .003 .04 − .07 − .17 to .04 .23
Higher educational level .09 − .02 to .19 .12 .18 .07–.29 .001
Cardiac historyd .08 − .03 to .18 .16 .04 − .07 to .15 .47
NYHA-class III .14 .03–.24 .01 .09 − .02 to .19 .12
LVEF .08 .03–.18 .15 .03 − .08 to .13 .61
COPD=Chronic obstructive pulmonary disease, DM=Diabetes mellitus, HF=heart
failure, LVEF=Left ventricular ejection fraction, NYHA=New York Heart Association
functional class.
a Adjusted for all other variables in the model.
b assessed by means of the BDI.
c assessed by means of the SAD4.
d History of CABG, PCI or MI.
⁎ Corresponding author at: Center of Psychology in Somatic diseases (CoRPS),
Tilburg University, P.O. Box 90153, 5000 LE Tilburg, The Netherlands. Tel.: +31 13 466
2115; fax: +31 13 466 2067.
E-mail address: a.j.m.pelle@uvt.nl (A.J. Pelle).
216 Letters to the Editor
Comorbid DM and/or COPD was common in HF outpatients, with
30.9% having either or both comorbidities. Comorbidities were
neither associated with increased levels of depressive symptoms nor
with mixed anxious and depressive symptoms. Although symptoms
statistically decreased during 12 months, clinical relevance was
negligible to small. Our ﬁndings corroborate studies demonstrating
that comorbid DM is not associated with clinical depression [10].
Depression and anxiety have been shown to be relatively stable over
time across cardiac conditions [13–16], including HF [17], which was
conﬁrmed in this study. The presence of comorbidities did not affect
these ﬁndings. Our ﬁndings are in contrast with studies suggesting
that comorbid COPD or DM may be associated with increased
depressive symptoms [5,22] and clinically relevant depression [10],
which may be explained by the administration of different instru-
ments. The results are opposed to the ﬁnding that comorbid diabetes
was associated with clinical anxiety in HF patients [10]. Although we
did not have information on clinical anxiety and depression, the SAD4
has been shown to be indicative for the presence of clinically relevant
anxiety and depression [20]. Caution is required in the interpretation
of the results for several reasons. Due to the small number of cases,
comorbid DM and/or COPD were combined into a single group, which
hampered our ability to examine differential associations of these
conditions. Second, no information was collected on the presence of
clinical diagnoses. Finally, information on co-morbid conditions was
obtained from medical records. Strengths of the current study
comprise the use of the psychometrically sound instruments, the
prospective and multicenter design. In summary, the present study
found that comorbid DM and/or COPDwas common in HF outpatients,
and that these comorbidities were neither independently
associated with depressive symptoms nor with mixed anxious and
depressive symptoms at 12 months. Depressive symptoms and mixed
anxious and depressive symptoms were clinically stable over time.
Future studies need to further explore the effects of comorbidities in
HF on patient-centered outcomes.
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